Poplar Point Capital Partners Purchases 70,685 Shares of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Stock

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) major shareholder Poplar Point Capital Partners bought 70,685 shares of the company’s stock in a transaction on Friday, January 31st. The shares were acquired at an average price of $0.65 per share, with a total value of $45,945.25. Following the transaction, the insider now directly owns 620,685 shares of the company’s stock, valued at approximately $403,445.25. This trade represents a 12.85 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Poplar Point Capital Partners also recently made the following trade(s):

• On Monday, January 27th, Poplar Point Capital Partners acquired 31,703 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average cost of $0.69 per share, for a total transaction of $21,875.07.
• On Thursday, February 20th, Poplar Point Capital Partners acquired 1,836 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average cost of $0.63 per share, with a total value of $1,156.68.
• On Tuesday, February 18th, Poplar Point Capital Partners acquired 3,222 shares of NovaBay Pharmaceuticals stock. The shares were purchased at an average price of $0.66 per share, with a total value of $2,126.52.
• On Monday, February 3rd, Poplar Point Capital Partners bought 2,597 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average cost of $0.64 per share, for a total transaction of $1,662.08.
• On Friday, March 7th, Poplar Point Capital Partners bought 102 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average cost of $0.55 per share, with a total value of $56.10.
• On Tuesday, March 4th, Poplar Point Capital Partners purchased 4,000 shares of NovaBay Pharmaceuticals stock. The shares were purchased at an average cost of $0.58 per share, for a total transaction of $2,320.00.
• On Thursday, February 27th, Poplar Point Capital Partners purchased 385 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average cost of $0.61 per share, for a total transaction of $234.85.
• On Tuesday, February 25th, Poplar Point Capital Partners acquired 25,033 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average cost of $0.62 per share, with a total value of $15,520.46.
• On Friday, March 14th, Poplar Point Capital Partners acquired 25,511 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average cost of $0.63 per share, for a total transaction of $16,071.93.
• On Wednesday, March 12th, Poplar Point Capital Partners acquired 11,837 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average price of $0.62 per share, with a total value of $7,338.94.

NovaBay Pharmaceuticals Stock Up 5.4 %

Shares of NovaBay Pharmaceuticals stock opened at $0.59 on Wednesday. NovaBay Pharmaceuticals, Inc. has a 52 week low of $0.36 and a 52 week high of $9.08. The firm has a market capitalization of $3.43 million, a P/E ratio of -0.01 and a beta of 0.90. The firm’s 50 day moving average is $0.60 and its two-hundred day moving average is $0.63.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on NovaBay Pharmaceuticals in a report on Thursday, April 10th. They issued a “hold” rating on the stock.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.